DarioHealth (DRIO) Receives Media Impact Score of 0.05
Press coverage about DarioHealth (NASDAQ:DRIO) has been trending somewhat positive on Sunday, Accern Sentiment reports. The research group rates the sentiment of media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. DarioHealth earned a coverage optimism score of 0.05 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 47.2957138122335 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Separately, Aegis began coverage on DarioHealth in a report on Tuesday, August 29th. They issued a “buy” rating and a $3.50 price objective on the stock.
Shares of DarioHealth (DRIO) opened at $1.68 on Friday. DarioHealth has a twelve month low of $1.40 and a twelve month high of $4.70.
DarioHealth Company Profile
DarioHealth Corp, formerly Labstyle Innovations Corp, is a digital health (mHealth) company. The Company is engaged in developing and commercializing a technology providing consumers with laboratory-testing capabilities using smart phones and other mobile devices. The Company’s product, Dario, also known as Dario Smart Diabetes Management Solution, is a mobile, real-time, cloud-based, diabetes management solution based on a software application combined with a pocket-sized, blood glucose monitoring device, Dario Smart Meter.
Receive News & Stock Ratings for DarioHealth Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DarioHealth Corp. and related stocks with our FREE daily email newsletter.